Argenx Se Quick Ratio (ARGX) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Argenx Se  (NASDAQ: ARGX)

Argenx Se's Quick Ratio

ARGX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Argenx Se's Cash & cash equivalent, this led to improvement in Argenx Se's Quick Ratio to 2.76, Quick Ratio remained below Argenx Se average.

Within Biotechnology & Pharmaceuticals industry 85 other companies have achieved higher Quick Ratio than Argenx Se in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 976, from total ranking in the third quarter 2025 at 1122.

Explain Quick Ratio?
How much Cash & cash equivalents ARGX´s has?
What are ARGX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARGX Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -4 % 97.07 % -11.62 % 97.07 % 57.69 %
Y / Y Cash & cash equivalent Change 132.76 % 132.76 % 45.04 % 132.76 % -26.79 %
Quick Ratio MRQ 2.76 2.64 2.05 2.64 1.14
ARGX's Total Ranking # 976 # 1122 # # #
Seq. Current Liabilities Change -4.02 % 29.92 % -23.03 % 0.02 % 97.03 %
Seq. Cash & cash equivalent Change 0 % 67.37 % -40.25 % 132.76 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 86
Healthcare Sector # 420
Overall Market # 976


Quick Ratio Statistics
High Average Low
4.84 3.09 2.24
(Dec 31 2023)   (Dec 31 2024)




Financial Statements
Argenx Se's Current Liabilities $ 1,267 Millions Visit ARGX's Balance sheet
Argenx Se's Cash & cash equivalent $ 3,491 Millions Visit ARGX's Balance sheet
Source of ARGX's Sales Visit ARGX's Sales by Geography


Cumulative Argenx Se's Quick Ratio

ARGX's Quick Ratio for the trailling 12 Months

ARGX Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 29.25 % 49.6 % 40.48 % 67.48 % 57.68 %
Y / Y Cash & cash equivalent TTM Growth 111.51 % 62.92 % 21.91 % 18.2 % -18.18 %
Quick Ratio TTM 2.55 2.12 1.98 1.78 1.56
Total Ranking TTM # 2860 # 3425 # # #
Seq. Current Liabilities TTM Growth -1.06 % 15.03 % -3 % 17.07 % 14.52 %
Seq. Cash & cash equivalent TTM Growth 18.84 % 23.22 % 8.17 % 33.54 % -8.46 %

Quick ratio ranking by company, industry and sector >> Back to ARGX Financial Strength Comparisons >> Go to Compare ARGX Quick Ratio to its Competitors

On the trailing twelve months basis ARGX Cash & cash equivalent more than doubled by 132.76 % in Q4 2025 year on year, while Current Liabilities decreased to $1,267 millions, this led to increase in in Argenx Se's Quick Ratio to 2.55, Quick Ratio remained below ARGX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 127 other companies have achieved higher Quick Ratio than Argenx Se. While Quick Ratio overall ranking has improved so far to 2860, from total ranking during the twelve months ending third quarter 2025 at 3425.

Explain Quick Ratio?
How much Cash & cash equivalents ARGX´s has?
What are ARGX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 128
Healthcare Sector # 775
Within the Market # 2860


trailing twelve months Quick Ratio Statistics
High Average Low
4.84 3.61 2.65
(Dec 31 2023)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Voyager Therapeutics Inc   7.40 $ 196.447  Millions$ 26.541  Millions
Scholar Rock Holding Corp  7.37 $ 367.563  Millions$ 49.869  Millions
Krystal Biotech Inc   7.27 $ 827.791  Millions$ 113.861  Millions
Metagenomi Therapeutics Inc   7.01 $ 160.799  Millions$ 22.933  Millions
Fennec Pharmaceuticals Inc   7.00 $ 73.576  Millions$ 10.518  Millions
Odyssey Therapeutics, Inc.  6.85 $ 181.358  Millions$ 26.475  Millions
Invivyd Inc   6.64 $ 226.689  Millions$ 34.163  Millions
Entera Bio Ltd   6.59 $ 7.108  Millions$ 1.079  Millions
Tenaya Therapeutics Inc   6.51 $ 100.547  Millions$ 15.436  Millions
Repligen Corp  6.51 $ 767.628  Millions$ 117.859  Millions
Engene Therapeutics Inc   6.47 $ 193.736  Millions$ 29.965  Millions
Acumen Pharmaceuticals Inc   6.03 $ 116.865  Millions$ 19.391  Millions
Solid Biosciences Inc   5.99 $ 187.850  Millions$ 31.369  Millions
Century Therapeutics inc   5.79 $ 117.114  Millions$ 20.226  Millions
Neumora Therapeutics Inc   5.67 $ 182.530  Millions$ 32.167  Millions
Fate Therapeutics Inc   5.65 $ 203.657  Millions$ 36.071  Millions
Intensity Therapeutics Inc   5.55 $ 11.921  Millions$ 2.146  Millions
Ginkgo Bioworks Holdings Inc   5.49 $ 422.620  Millions$ 77.024  Millions
Caribou Biosciences Inc   5.48 $ 139.340  Millions$ 25.414  Millions
Pharmacyte Biotech Inc   5.33 $ 15.538  Millions$ 2.914  Millions
Atyr Pharma Inc   5.19 $ 78.687  Millions$ 15.148  Millions
Revolution Medicines Inc   5.10 $ 2,025.679  Millions$ 397.391  Millions
Qiagen N v   5.07 $ 1,044.265  Millions$ 206.089  Millions
Vir Biotechnology Inc   4.99 $ 462.860  Millions$ 92.815  Millions
Lineage Cell Therapeutics Inc   4.91 $ 55.781  Millions$ 11.367  Millions
Recursion Pharmaceuticals Inc   4.90 $ 743.294  Millions$ 151.619  Millions
Kodiak Sciences Inc   4.87 $ 209.862  Millions$ 43.113  Millions
Alpha Cognition Inc.  4.75 $ 66.047  Millions$ 13.893  Millions
Prime Medicine Inc   4.74 $ 177.680  Millions$ 37.448  Millions
Agomab Therapeutics Nv  4.65 $ 96.788  Millions$ 20.820  Millions

Date modified: 2026-07-07T09:15:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.